Genus PLC (GNS.L)
11 Dec 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|72||2010||Non-Executive Independent Chairman of the Board|
|2011||Chief Executive, Executive Director|
|2013||Group Finance Director, Executive Director|
|2013||Chief Scientific Officer and Head of Genus R&D|
|2014||Group General Counsel & Company Secretary|
- 3 Healthcare Stocks With More Downside Than Upside? Shire PLC, Alliance Pharma plc And Genus plc
- AstraZeneca plc, Smith & Nephew plc And Genus plc: Buy, Sell Or Hold?
- GlaxoSmithKline plc, Genus plc And Alliance Pharma plc: 3 Of The Best Health Care Stocks?
- Does Sepura Plc Offer More Value Than Genus plc & SDL plc After A 24% Rally?
- Is AstraZeneca plc A Better Buy Than BTG plc, Dechra Pharmaceuticals plc And Genus plc?
- Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?